<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ANTI-D (RH0) IMMUNOGLOBULIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ANTI-D (RH0) IMMUNOGLOBULIN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#handlingAndStorage" data-toggle="tab">Handling and storage</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">To rhesus-negative woman for prevention of Rh&#8320;(D) sensitisation, following birth of rhesus-positive infant</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                500 units, dose to be administered immediately or within 72 hours; for transplacental bleed of over 4 mL fetal red cells, extra 100&#8211;125 units per mL fetal red cells, subcutaneous route used for patients with bleeding disorders.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">To rhesus-negative woman for prevention of Rh&#8320;(D) sensitisation, following any potentially sensitising episode (e.g. stillbirth, abortion, amniocentesis) up to 20 weeks' gestation</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                250 units per episode, dose to be administered immediately or within 72 hours, subcutaneous route used for patients with bleeding disorders.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">To rhesus-negative woman for prevention of Rh&#8320;(D) sensitisation, following any potentially sensitising episode (e.g. stillbirth, abortion, amniocentesis) after 20 weeks' gestation</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                500 units per episode, dose to be administered immediately or within 72 hours, subcutaneous route used for patients with bleeding disorders.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">To rhesus-negative woman for prevention of Rh&#8320;(D) sensitisation, antenatal prophylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                500 units, dose to be given at weeks 28 and 34 of pregnancy, if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, subcutaneous route used for patients with bleeding disorders.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">To rhesus-negative woman for prevention of Rh&#8320;(D) sensitisation, antenatal prophylaxis (alternative NICE recommendation)</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                1000&#8211;1650 units, dose to be given at weeks 28 and 34 of pregnancy, alternatively 1500 units for 1 dose, dose to be given between 28 and 34 weeks gestation.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">To rhesus-negative woman for prevention of Rh&#8320;(D) sensitisation, following Rh&#8320;(D) incompatible blood transfusion</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                100&#8211;125 units/mL, dose per mL transfused rhesus-positive red cells given, subcutaneous route used for patients with bleeding disorders.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>






      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Treatment of idiopathic thrombocytopenia purpura in rhesus negative patients</li>
            <li>treatment of idiopathic thrombocytopenia purpura in splenectomised patients</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>rare:</strong> Anaphylaxis, dyspnoea, hypotension, tachycardia, urticaria,
              </p>
              <p>
                <strong>notKnown:</strong> Abdominal pain, arthralgia, asthenia, back pain, diarrhoea, dizziness, drowsiness, fever, headache, hypertension, hypotension, injection site pain, malaise, myalgia, nausea, pruritus, rash, sweating, vomiting,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> abdominal distension, abdominal pain, blood pressure fluctuations, deep vein thrombosis, haemolytic anaemia, injection site reactions, myocardial infarction, pulmonary embolism, stroke, thromboembolic events,
              </p>
        
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA156</h3>
              <p outputclass="title">Routine antenatal anti-D prophylaxis for rhesus-negative women (August 2008)</p> <p>Routine antenatal anti-D prophylaxis should be offered to all non-sensitised pregnant women who are rhesus negative.</p><xref format="html" href="http://www.nice.org.uk/TA156">www.nice.org.uk/TA156</xref>
                <a href="http://www.nice.org.uk/TA156" target="_blank">www.nice.org.uk/TA156</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Immunoglobulin A deficiency
          </li>
          <li>
            possible interference with live virus vaccines
          </li>
        </ul>
        <ul>
          <li>
            <p>MMR vaccine may be given in the postpartum period with anti-D (Rh0) immunoglobulin injection provided that separate syringes are used and the products are administered into different limbs. If blood is transfused, the antibody response to the vaccine may be inhibited&#8212;measure rubella antibodies after 6&#8211;8 weeks and revaccinate if necessary.</p>
          </li>
        </ul>
      </section>






      <section class="tab-pane" id="handlingAndStorage">
        <h2>Advice regarding handling and storage</h2>

            <section class="handlingAndStorage">
              <p>Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. <b>Refrigerated storage</b> is usually necessary; many immunoglobulins need to be stored at 2&#8211;8&#176;C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.</p>
            </section>
      </section>







      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ANTI-D (RH0) IMMUNOGLOBULIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76022"><a href="../medicinalForm/PHP76022.html" data-target="#PHP76022" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
